Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study

Autores: Ledermann, J. A.; Shapira-Frommer, R. ; Santin, A.; Lisyanskaya, A. S.; Pignata, S.; Vergote, I.; Raspagliesi, F. ; Sonke, G. S. ; Birrer, M. J.; Provencher, D. M. ; Sehouli, J.; Colombo, N.; González Martín, Antonio; Oaknin, A.; Ottevanger, P. B.; Rudaitis, V.; Cristescu, R.; Kobie, J.; Ruman, J.; Matulonis, U. A.